423 related articles for article (PubMed ID: 20003971)
21. En bloc esophagectomy reduces local recurrence and improves survival compared with transhiatal resection after neoadjuvant therapy for esophageal adenocarcinoma.
Rizzetto C; DeMeester SR; Hagen JA; Peyre CG; Lipham JC; DeMeester TR
J Thorac Cardiovasc Surg; 2008 Jun; 135(6):1228-36. PubMed ID: 18544359
[TBL] [Abstract][Full Text] [Related]
22. Treatment of Barrett's esophagus with high-grade dysplasia.
McAllaster JD; Buckles D; Al-Kasspooles M
Expert Rev Anticancer Ther; 2009 Mar; 9(3):303-16. PubMed ID: 19275509
[TBL] [Abstract][Full Text] [Related]
23. Barrett's esophagus.
Falk GW
Gastrointest Endosc Clin N Am; 1994 Oct; 4(4):773-89. PubMed ID: 7812646
[TBL] [Abstract][Full Text] [Related]
24. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
25. Signet-ring cell or mucinous histology after preoperative chemoradiation and survival in patients with esophageal or esophagogastric junction adenocarcinoma.
Chirieac LR; Swisher SG; Correa AM; Ajani JA; Komaki RR; Rashid A; Hamilton SR; Wu TT
Clin Cancer Res; 2005 Mar; 11(6):2229-36. PubMed ID: 15788671
[TBL] [Abstract][Full Text] [Related]
26. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett's oesophagus.
Pech O; Behrens A; May A; Nachbar L; Gossner L; Rabenstein T; Manner H; Guenter E; Huijsmans J; Vieth M; Stolte M; Ell C
Gut; 2008 Sep; 57(9):1200-6. PubMed ID: 18460553
[TBL] [Abstract][Full Text] [Related]
27. Low prevalence of submucosal invasive carcinoma at esophagectomy for high-grade dysplasia or intramucosal adenocarcinoma in Barrett's esophagus: a 20-year experience.
Wang VS; Hornick JL; Sepulveda JA; Mauer R; Poneros JM
Gastrointest Endosc; 2009 Apr; 69(4):777-83. PubMed ID: 19136106
[TBL] [Abstract][Full Text] [Related]
28. [Current diagnosis and therapy of esophageal carcinoma].
Mühr-Wilkenshoff F; Stahl M; Faiss S; Zeitz M; Scherübl H
Z Gastroenterol; 2004 Jul; 42(7):615-21. PubMed ID: 15248111
[TBL] [Abstract][Full Text] [Related]
29. Retrospective review of patients with locally advanced esophageal cancer treated at the University of Pittsburgh.
Defoe SG; Pennathur A; Flickinger JC; Heron DE; Gibson MK; Luketich JD; Greenberger JS
Am J Clin Oncol; 2011 Dec; 34(6):587-92. PubMed ID: 22101387
[TBL] [Abstract][Full Text] [Related]
30. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation.
Gu Y; Swisher SG; Ajani JA; Correa AM; Hofstetter WL; Liao Z; Komaki RR; Rashid A; Hamilton SR; Wu TT
Cancer; 2006 Mar; 106(5):1017-25. PubMed ID: 16456809
[TBL] [Abstract][Full Text] [Related]
31. Is extended volume external beam radiation therapy covering the anastomotic site beneficial in post-esophagectomy high risk patients?
Yu E; Dar R; Rodrigues GB; Stitt L; Videtic GM; Truong P; Tomiak A; Ash R; Brecevic E; Inculet R; Malthaner R; Vincent M; Craig I; Kocha W; Lefcoe M
Radiother Oncol; 2004 Nov; 73(2):141-8. PubMed ID: 15542160
[TBL] [Abstract][Full Text] [Related]
32. Surgical management of Barrett's esophagus.
Clark GW; DeMeester TR
Ann Chir Gynaecol; 1995; 84(2):139-44. PubMed ID: 7574371
[TBL] [Abstract][Full Text] [Related]
33. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients.
Liao Z; Zhang Z; Jin J; Ajani JA; Swisher SG; Stevens CW; Ho L; Smythe R; Vaporciyan AA; Putnam JB; Walsh GL; Roth JA; Yao JC; Allen PK; Cox JD; Komaki R
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1484-93. PubMed ID: 15590179
[TBL] [Abstract][Full Text] [Related]
34. Barrett's esophagus-is it bad for your health?
Falk GW
Am J Gastroenterol; 2005 Dec; 100(12):2622-3. PubMed ID: 16393210
[TBL] [Abstract][Full Text] [Related]
35. Genetic mechanisms of TP53 loss of heterozygosity in Barrett's esophagus: implications for biomarker validation.
Wongsurawat VJ; Finley JC; Galipeau PC; Sanchez CA; Maley CC; Li X; Blount PL; Odze RD; Rabinovitch PS; Reid BJ
Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):509-16. PubMed ID: 16537709
[TBL] [Abstract][Full Text] [Related]
36. Intraepithelial high-grade neoplasia and early adenocarcinoma in short-segment Barrett's esophagus (SSBE): curative treatment using local endoscopic treatment techniques.
May A; Gossner L; Pech O; Müller H; Vieth M; Stolte M; Ell C
Endoscopy; 2002 Aug; 34(8):604-10. PubMed ID: 12173079
[TBL] [Abstract][Full Text] [Related]
37. Pathologic prognostic factors in Barrett's associated adenocarcinoma: a follow-up study of 96 patients.
Torres C; Turner JR; Wang HH; Richards W; Sugarbaker D; Shahsafaei A; Odze RD
Cancer; 1999 Feb; 85(3):520-8. PubMed ID: 10091725
[TBL] [Abstract][Full Text] [Related]
38. Barrett's esophagus, high-grade dysplasia, and early adenocarcinoma: a pathological study.
Cameron AJ; Carpenter HA
Am J Gastroenterol; 1997 Apr; 92(4):586-91. PubMed ID: 9128304
[TBL] [Abstract][Full Text] [Related]
39. Improved outcomes in the management of esophageal cancer with the addition of surgical resection to chemoradiation therapy.
McKenzie S; Mailey B; Artinyan A; Metchikian M; Shibata S; Kernstine K; Kim J
Ann Surg Oncol; 2011 Feb; 18(2):551-8. PubMed ID: 20839062
[TBL] [Abstract][Full Text] [Related]
40. Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer.
Meredith KL; Weber JM; Turaga KK; Siegel EM; McLoughlin J; Hoffe S; Marcovalerio M; Shah N; Kelley S; Karl R
Ann Surg Oncol; 2010 Apr; 17(4):1159-67. PubMed ID: 20140529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
